RTOG 0913: A phase 1 study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma

International Journal of Radiation Oncology Biology Physics

Volumn 86, Issue 5, 2013, Pages 880-884

  Chinnaiyan, Prakash ^a   Won, Minhee ^b   Wen, Patrick Y ^c   Rojiani, Amyn M ^d   Wendland, Merideth ^e   Dipetrillo, Thomas A ^f   Corn, Benjamin W ^g   Mehta, Minesh P ^h  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b RADIATION THERAPY ONCOLOGY GROUP   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d MEDICAL COLLEGE OF GEORGIA   (United States)

^e Radiation Oncology   (United States)

^f RHODE ISLAND HOSPITAL   (United States)

^g TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^h UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOSE LIMITING TOXICITY; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; MAXIMUM TOLERATED DOSE; METHODS AND MATERIALS; MOLECULAR DETERMINANTS; NEWLY DIAGNOSED GLIOBLASTOMA; RADIATION THERAPY ONCOLOGY GROUPS;

RADIOTHERAPY;

TOXICITY;

BIOLOGICAL MARKER; EVEROLIMUS; TEMOZOLOMIDE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER RADIOTHERAPY; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; DEATH; DRUG DOSE ESCALATION; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GAIT DISORDER; GLIOBLASTOMA; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; HYPONATREMIA; HYPOXIA; INSOMNIA; LYMPHOCYTOPENIA; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; OTALGIA; PAPULOPUSTULAR RASH; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RASH; RESPIRATORY TRACT INFECTION; SIDE EFFECT; THROMBOCYTOPENIA; TUMOR GROWTH;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DACARBAZINE; DOSE FRACTIONATION; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; SIROLIMUS;

EID: 84880045561     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2013.04.036     Document Type: Article

References (21)

1. R. Stupp, W.P. Mason, and M.J. van den Bent Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 2005 987 996 (Pubitemid 40349501)
2. P.Y. Wen, and S. Kesari Malignant gliomas in adults N Engl J Med 359 2008 492 507
3. Cancer Genome Atlas Research Network Comprehensive genomic characterization defines human glioblastoma genes and core pathways Nature 455 2008 1061 1068
4. A. Chakravarti, G. Zhai, and Y. Suzuki The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas J Clin Oncol 22 2004 1926 1933 (Pubitemid 41095185)
5. I.K. Mellinghoff, M.Y. Wang, and I. Vivanco Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors N Engl J Med 353 2005 2012 2024 (Pubitemid 41609094)
6. J.M. Albert, K.W. Kim, and C. Cao Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer Mol Cancer Ther 5 2006 1183 1189 (Pubitemid 43881310)
7. C. Cao, T. Subhawong, and J.M. Albert Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells Cancer Res 66 2006 10040 10047 (Pubitemid 44672057)
8. J.S. Eshleman, B.L. Carlson, and A.C. Mladek Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy Cancer Res 62 2002 7291 7297 (Pubitemid 36025252)
9. E.T. Shinohara, C. Cao, and K. Niermann Enhanced radiation damage of tumor vasculature by mTOR inhibitors Oncogene 24 2005 5414 5422 (Pubitemid 43080085)
10. D.F. Lee, H.P. Kuo, and C.T. Chen IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway Cell 130 2007 440 455
11. R.J. Motzer, B. Escudier, and S. Oudard Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 2008 449 456
12. J. Baselga, M. Campone, and M. Piccart Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer N Engl J Med 366 2012 520 529
13. J.C. Yao, M.H. Shah, and T. Ito Everolimus for advanced pancreatic neuroendocrine tumors N Engl J Med 364 2011 514 523
14. D.A. Krueger, M.M. Care, and K. Holland Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis N Engl J Med 363 2010 1801 1811
15. W.P. Mason, M. Macneil, and P. Kavan A phase I study of temozolomide and everolimus (RAD001) in patients with newly diagnosed and progressive glioblastoma either receiving or not receiving enzyme-inducing anticonvulsants: an NCIC CTG study Invest New Drugs 30 2012 2344 2351
16. J.N. Sarkaria, E. Galanis, and W. Wu North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme Int J Radiat Oncol Biol Phys 81 2011 468 475
17. C. Tanaka, T. O'Reilly, and J.M. Kovarik Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data J Clin Oncol 26 2008 1596 1602
18. H.S. Shiah, C.Y. Chen, and C.Y. Dai Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma Aliment Pharmacol Ther 37 2013 62 73
19. K. Tanaka, T. Sasayama, and K. Mizukawa Specific mTOR inhibitor rapamycin enhances cytotoxicity induced by alkylating agent 1-(4-amino-2-methyl-5- pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea (ACNU) in human U251 malignant glioma cells J Neurooncol 84 2007 233 244
20. S.A. Schaffer, and H.J. Ross Everolimus: efficacy and safety in cardiac transplantation Expert Opin Drug Saf 9 2010 843 854
21. J.N. Sarkaria, E. Galanis, and W. Wu Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risks Clin Cancer Res 16 2010 5573 5580